References
- 1. EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53(3):397-417.
- 2. SCHRIER RW. Water and sodium retention in edematous disorders: Role of vasopressin and aldosterone. Am J Med. 2006; 119(7 Suppl 1):S47-53.
- 3. ADROGUÉ HJ, MADIAS NE. Hyponatremia. N Engl J Med. 2000; 342(21):1581-9.
- 4. BIGGINS SW, RODRIGUEZ HJ, BACCHETTI P, BASS NM, ROBERTS JP, TERRAULT NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005; 41(1):32-39.
- 5. GINÈS P, CÁRDENAS A. The management of ascites and hyponatremia in cirrhosis. Semin Liver Dis. 2008; 28(1):43-58.
- 6. FOLLO A, LLOVET JM, NAVASA M, PLANAS R, FORNS X, FRANCITORRA A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994; 20(6): 1495-1501.
- 7. ARROYO V, RODÉS J, GUTIÉRREZ-LIZÁRRAGA MA, REVERT L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis. 1976; 21(3):249-56.
- 8. LONDOÑO MC, GUEVARA M, RIMOLA A, NAVASA M, TAURÀ P, MAS A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006; 130(4):1135-43.
- 9. SOLÀ E, WATSON H, GRAUPERA I, TURÓN F, BARRETO R, RODRÍGUEZ E, et al. Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema. J Hepatol. 2012; 57(6):1199-206.
- 10. PEREIRA G, GUEVARA M, FAGUNDES C, SOLÁ E, RODRÍGUEZ E, FERNÁNDEZ J, et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol. 2012; 56(5):1040-46.
- 11. CÁRDENAS A, GINÈS P, MAROTTA P, CZERWIEC F, OYUANG J, GUEVARA M, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012; 56(3):571-8.
- 12. BERL T, QUITTNAT-PELLETIER F, VERBALIS JG, SCHRIER RW, BICHET DG, OUYANG J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010; 21(4):705-12.